MEDICAL business Tissue Regenix has received approval to carry out a clinical research trial of a product to treat acute wounds.

Tissue Regenix, based at York Science Park, has developed a patented process, called dCell, to “wash” the DNA from animal tissues, such as knee tissue and heart valves, enabling it to be used in human transplants.

Its dCELL dermis matrix has already been trialled in the treatment of chronic wounds and the new study will test its effectiveness against wounds ranging from surgical incisions and traumatic injuries to bites and burns.

The company said the trial marked an important milestone in Tissue Regenix’s plans to target the global market for chronic and acute wound care, which is estimated to be worth about $21 billion by 2015.